Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiovascular Diseases | 92 | 2024 | 15502 | 4.820 |
Why?
|
Lipoproteins | 24 | 2024 | 881 | 4.740 |
Why?
|
Cholesterol, LDL | 44 | 2024 | 2382 | 3.940 |
Why?
|
Cholesterol, HDL | 32 | 2023 | 1814 | 3.930 |
Why?
|
Lipoproteins, LDL | 16 | 2020 | 642 | 3.500 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 34 | 2024 | 3246 | 3.460 |
Why?
|
Fasting | 19 | 2021 | 1603 | 3.280 |
Why?
|
Lipoprotein(a) | 16 | 2024 | 480 | 3.210 |
Why?
|
Triglycerides | 33 | 2022 | 2461 | 2.900 |
Why?
|
Fluorobenzenes | 9 | 2014 | 179 | 2.650 |
Why?
|
Primary Prevention | 16 | 2024 | 1186 | 2.510 |
Why?
|
Fatty Acids, Omega-3 | 20 | 2024 | 1390 | 2.400 |
Why?
|
Atherosclerosis | 27 | 2023 | 3407 | 2.170 |
Why?
|
Lipids | 16 | 2024 | 3341 | 2.060 |
Why?
|
Dyslipidemias | 10 | 2024 | 868 | 2.050 |
Why?
|
Amino Acids, Branched-Chain | 9 | 2022 | 269 | 2.010 |
Why?
|
Coronary Disease | 15 | 2024 | 5914 | 1.890 |
Why?
|
Aspirin | 13 | 2022 | 3133 | 1.840 |
Why?
|
Lipoproteins, HDL | 10 | 2024 | 676 | 1.730 |
Why?
|
Polysaccharides | 9 | 2024 | 1014 | 1.670 |
Why?
|
Women's Health | 15 | 2021 | 2065 | 1.640 |
Why?
|
Diet, Mediterranean | 5 | 2024 | 740 | 1.640 |
Why?
|
Sulfonamides | 10 | 2017 | 1979 | 1.540 |
Why?
|
Hypertriglyceridemia | 6 | 2021 | 293 | 1.390 |
Why?
|
Inflammation | 20 | 2024 | 10774 | 1.350 |
Why?
|
C-Reactive Protein | 16 | 2022 | 3826 | 1.320 |
Why?
|
Postprandial Period | 9 | 2020 | 315 | 1.280 |
Why?
|
Pyrimidines | 9 | 2014 | 3028 | 1.280 |
Why?
|
Insulin Resistance | 12 | 2024 | 3964 | 1.260 |
Why?
|
Apolipoprotein A-I | 7 | 2020 | 299 | 1.250 |
Why?
|
Diabetes Mellitus, Type 2 | 21 | 2024 | 12149 | 1.150 |
Why?
|
Platelet Aggregation Inhibitors | 10 | 2022 | 2751 | 1.140 |
Why?
|
Lipoproteins, VLDL | 7 | 2020 | 201 | 1.100 |
Why?
|
Risk Assessment | 38 | 2024 | 23996 | 1.100 |
Why?
|
Risk Factors | 89 | 2024 | 74213 | 1.080 |
Why?
|
Exercise | 9 | 2022 | 5890 | 1.080 |
Why?
|
Acute-Phase Proteins | 6 | 2023 | 250 | 1.040 |
Why?
|
Cholesterol | 12 | 2023 | 2905 | 1.030 |
Why?
|
Acetylglucosamine | 4 | 2023 | 189 | 1.030 |
Why?
|
Vitamin D | 15 | 2024 | 3303 | 1.010 |
Why?
|
Apolipoproteins B | 7 | 2023 | 386 | 0.960 |
Why?
|
Exercise Test | 6 | 2021 | 2127 | 0.940 |
Why?
|
Magnetic Resonance Spectroscopy | 13 | 2024 | 3769 | 0.940 |
Why?
|
Cholecalciferol | 9 | 2024 | 553 | 0.930 |
Why?
|
Dietary Supplements | 21 | 2024 | 3415 | 0.930 |
Why?
|
Hyperlipidemias | 3 | 2021 | 771 | 0.920 |
Why?
|
Middle Aged | 119 | 2024 | 220921 | 0.870 |
Why?
|
C-Peptide | 1 | 2024 | 440 | 0.830 |
Why?
|
Female | 150 | 2024 | 392705 | 0.820 |
Why?
|
Humans | 218 | 2024 | 761596 | 0.820 |
Why?
|
Particle Size | 11 | 2023 | 1648 | 0.800 |
Why?
|
Apolipoproteins | 6 | 2022 | 326 | 0.790 |
Why?
|
Food Labeling | 1 | 2024 | 179 | 0.760 |
Why?
|
Proportional Hazards Models | 21 | 2024 | 12463 | 0.740 |
Why?
|
Fishes | 2 | 2024 | 603 | 0.720 |
Why?
|
Ventricular Premature Complexes | 1 | 2021 | 112 | 0.720 |
Why?
|
Incidence | 28 | 2024 | 21355 | 0.710 |
Why?
|
Aged | 85 | 2024 | 169310 | 0.700 |
Why?
|
Glycosylation | 9 | 2024 | 1097 | 0.700 |
Why?
|
Group II Phospholipases A2 | 1 | 2019 | 12 | 0.670 |
Why?
|
Double-Blind Method | 25 | 2024 | 12341 | 0.660 |
Why?
|
Coronary Artery Disease | 8 | 2022 | 6403 | 0.640 |
Why?
|
Anticholesteremic Agents | 4 | 2016 | 966 | 0.640 |
Why?
|
Glycoproteins | 2 | 2016 | 2203 | 0.620 |
Why?
|
Blood Chemical Analysis | 5 | 2019 | 437 | 0.620 |
Why?
|
Tunica Intima | 3 | 2012 | 459 | 0.610 |
Why?
|
Carbohydrates | 1 | 2020 | 390 | 0.610 |
Why?
|
Kringles | 1 | 2017 | 8 | 0.600 |
Why?
|
Spouses | 1 | 2020 | 283 | 0.600 |
Why?
|
Acute Coronary Syndrome | 4 | 2020 | 2190 | 0.590 |
Why?
|
Apolipoprotein B-100 | 3 | 2020 | 157 | 0.580 |
Why?
|
Inflammation Mediators | 3 | 2018 | 1886 | 0.580 |
Why?
|
Follow-Up Studies | 33 | 2022 | 39106 | 0.580 |
Why?
|
Calcinosis | 2 | 2022 | 1469 | 0.560 |
Why?
|
Body Mass Index | 19 | 2022 | 12953 | 0.530 |
Why?
|
Male | 99 | 2024 | 360846 | 0.530 |
Why?
|
Acetylgalactosamine | 1 | 2016 | 38 | 0.530 |
Why?
|
Prospective Studies | 36 | 2024 | 54423 | 0.530 |
Why?
|
Diagnostic Tests, Routine | 1 | 2021 | 787 | 0.490 |
Why?
|
Light | 1 | 2021 | 1353 | 0.480 |
Why?
|
Tunica Media | 2 | 2012 | 112 | 0.470 |
Why?
|
Obesity | 14 | 2023 | 12947 | 0.450 |
Why?
|
Deoxyglucose | 1 | 2014 | 333 | 0.450 |
Why?
|
Myocardial Ischemia | 2 | 2018 | 2113 | 0.450 |
Why?
|
Docosahexaenoic Acids | 5 | 2024 | 907 | 0.450 |
Why?
|
Biological Specimen Banks | 1 | 2019 | 783 | 0.440 |
Why?
|
Proteins | 4 | 2020 | 6032 | 0.440 |
Why?
|
Heptanoic Acids | 2 | 2014 | 344 | 0.440 |
Why?
|
Heart Rate | 4 | 2021 | 4195 | 0.440 |
Why?
|
Carotid Artery Diseases | 2 | 2012 | 877 | 0.440 |
Why?
|
Myocardial Infarction | 9 | 2023 | 11461 | 0.430 |
Why?
|
Prognosis | 23 | 2024 | 29629 | 0.410 |
Why?
|
Predictive Value of Tests | 14 | 2024 | 15266 | 0.400 |
Why?
|
Stroke | 12 | 2023 | 9758 | 0.400 |
Why?
|
Blood Glucose | 3 | 2024 | 6391 | 0.380 |
Why?
|
Fibrinogen | 3 | 2018 | 888 | 0.380 |
Why?
|
Cacao | 2 | 2022 | 98 | 0.380 |
Why?
|
Risk | 10 | 2019 | 9610 | 0.360 |
Why?
|
Cause of Death | 5 | 2024 | 3683 | 0.360 |
Why?
|
Insulin | 2 | 2024 | 6597 | 0.360 |
Why?
|
Vitamins | 8 | 2023 | 1635 | 0.350 |
Why?
|
Postmenopause | 2 | 2021 | 2513 | 0.350 |
Why?
|
Mortality | 3 | 2024 | 2902 | 0.350 |
Why?
|
Thyroid Gland | 3 | 2024 | 1170 | 0.350 |
Why?
|
Polymorphism, Single Nucleotide | 13 | 2021 | 15936 | 0.350 |
Why?
|
Practice Guidelines as Topic | 5 | 2017 | 7391 | 0.340 |
Why?
|
Pyrroles | 2 | 2014 | 1125 | 0.330 |
Why?
|
Time Factors | 14 | 2024 | 39969 | 0.320 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2018 | 10212 | 0.320 |
Why?
|
Cell Fractionation | 1 | 2009 | 251 | 0.320 |
Why?
|
Hemorrhage | 2 | 2018 | 3424 | 0.310 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 5 | 2018 | 509 | 0.310 |
Why?
|
Clinical Laboratory Techniques | 2 | 2016 | 746 | 0.310 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 3415 | 0.310 |
Why?
|
Aortic Valve Stenosis | 4 | 2023 | 2001 | 0.310 |
Why?
|
Diet | 4 | 2024 | 8075 | 0.300 |
Why?
|
Preventive Medicine | 1 | 2010 | 246 | 0.300 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2020 | 1126 | 0.300 |
Why?
|
Eicosapentaenoic Acid | 5 | 2024 | 561 | 0.300 |
Why?
|
Sex Characteristics | 2 | 2021 | 2639 | 0.300 |
Why?
|
Cohort Studies | 18 | 2024 | 41495 | 0.300 |
Why?
|
Hypertension | 7 | 2021 | 8540 | 0.300 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 2009 | 140 | 0.290 |
Why?
|
Atrioventricular Block | 1 | 2009 | 133 | 0.290 |
Why?
|
Hypothyroidism | 3 | 2021 | 668 | 0.280 |
Why?
|
Survival Rate | 5 | 2021 | 12723 | 0.280 |
Why?
|
Hypercholesterolemia | 4 | 2018 | 1141 | 0.280 |
Why?
|
Fibrinolytic Agents | 1 | 2016 | 2084 | 0.270 |
Why?
|
Chest Pain | 1 | 2013 | 1091 | 0.270 |
Why?
|
Risk Reduction Behavior | 4 | 2016 | 1112 | 0.270 |
Why?
|
Motor Activity | 4 | 2011 | 2715 | 0.270 |
Why?
|
Guidelines as Topic | 2 | 2010 | 1386 | 0.270 |
Why?
|
Neoplasms | 12 | 2022 | 22173 | 0.260 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8002 | 0.260 |
Why?
|
Eating | 1 | 2012 | 1539 | 0.260 |
Why?
|
Atrial Fibrillation | 4 | 2021 | 5127 | 0.260 |
Why?
|
Hyperglycemia | 1 | 2014 | 1376 | 0.260 |
Why?
|
Decision Making | 2 | 2016 | 3929 | 0.260 |
Why?
|
Age Factors | 7 | 2021 | 18399 | 0.250 |
Why?
|
United States | 19 | 2024 | 72340 | 0.250 |
Why?
|
Benchmarking | 3 | 2024 | 1045 | 0.250 |
Why?
|
Life Style | 3 | 2022 | 3917 | 0.250 |
Why?
|
Diabetic Retinopathy | 1 | 2014 | 1274 | 0.240 |
Why?
|
Hypolipidemic Agents | 2 | 2020 | 609 | 0.240 |
Why?
|
Cross-Sectional Studies | 14 | 2023 | 26129 | 0.240 |
Why?
|
Thyroxine | 3 | 2024 | 666 | 0.240 |
Why?
|
Cholesterol, VLDL | 2 | 2017 | 70 | 0.240 |
Why?
|
Sex Factors | 7 | 2020 | 10554 | 0.230 |
Why?
|
Case-Control Studies | 7 | 2024 | 22176 | 0.230 |
Why?
|
Carotid Arteries | 2 | 2011 | 941 | 0.220 |
Why?
|
Nutrition Surveys | 3 | 2016 | 1733 | 0.220 |
Why?
|
Program Evaluation | 1 | 2012 | 2495 | 0.220 |
Why?
|
Molecular Weight | 2 | 2020 | 2186 | 0.220 |
Why?
|
Consensus | 8 | 2022 | 3124 | 0.220 |
Why?
|
Glomerular Filtration Rate | 3 | 2022 | 2178 | 0.210 |
Why?
|
Blood Pressure | 5 | 2018 | 8481 | 0.210 |
Why?
|
Colorectal Neoplasms | 4 | 2016 | 6938 | 0.210 |
Why?
|
Placebos | 2 | 2020 | 1667 | 0.210 |
Why?
|
Treatment Outcome | 14 | 2024 | 64685 | 0.210 |
Why?
|
Leucine | 2 | 2021 | 548 | 0.200 |
Why?
|
Adult | 32 | 2024 | 221210 | 0.200 |
Why?
|
Vitamin E | 3 | 2018 | 872 | 0.200 |
Why?
|
Hyperthyroidism | 2 | 2021 | 294 | 0.200 |
Why?
|
Metabolomics | 2 | 2024 | 1659 | 0.200 |
Why?
|
Diabetes Mellitus | 4 | 2019 | 5841 | 0.200 |
Why?
|
Communications Media | 1 | 2022 | 42 | 0.190 |
Why?
|
Health Promotion | 2 | 2022 | 2214 | 0.190 |
Why?
|
Adiposity | 3 | 2021 | 1879 | 0.180 |
Why?
|
Models, Theoretical | 1 | 2013 | 3575 | 0.180 |
Why?
|
Disease Progression | 2 | 2019 | 13510 | 0.180 |
Why?
|
Seafood | 1 | 2024 | 393 | 0.180 |
Why?
|
Immunoglobulin G | 3 | 2024 | 4544 | 0.180 |
Why?
|
Breast Neoplasms | 5 | 2022 | 21019 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6484 | 0.180 |
Why?
|
Reference Values | 3 | 2020 | 4920 | 0.180 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2014 | 2242 | 0.180 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1809 | 0.170 |
Why?
|
Genome-Wide Association Study | 9 | 2024 | 12690 | 0.170 |
Why?
|
Fish Oils | 2 | 2023 | 483 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2019 | 1475 | 0.170 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2319 | 0.170 |
Why?
|
Mendelian Randomization Analysis | 3 | 2021 | 1007 | 0.170 |
Why?
|
Angina, Unstable | 3 | 2013 | 888 | 0.170 |
Why?
|
Apolipoprotein E4 | 1 | 2024 | 709 | 0.170 |
Why?
|
Chemistry, Clinical | 2 | 2016 | 64 | 0.160 |
Why?
|
Societies, Medical | 4 | 2020 | 3905 | 0.160 |
Why?
|
Diet, Carbohydrate-Restricted | 1 | 2022 | 262 | 0.160 |
Why?
|
Patient Compliance | 2 | 2024 | 2690 | 0.160 |
Why?
|
Morbidity | 2 | 2017 | 1752 | 0.160 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 318 | 0.160 |
Why?
|
Oxylipins | 1 | 2019 | 53 | 0.160 |
Why?
|
Heart Failure | 5 | 2024 | 11671 | 0.160 |
Why?
|
Peripheral Arterial Disease | 3 | 2019 | 1273 | 0.160 |
Why?
|
Hemostasis | 1 | 2021 | 467 | 0.160 |
Why?
|
Multivariate Analysis | 5 | 2017 | 12059 | 0.150 |
Why?
|
Cardiology | 3 | 2019 | 1656 | 0.150 |
Why?
|
Diet, Reducing | 1 | 2022 | 485 | 0.150 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2019 | 225 | 0.150 |
Why?
|
Vitamin D Deficiency | 3 | 2024 | 1388 | 0.150 |
Why?
|
Fatty Acids | 3 | 2023 | 1808 | 0.150 |
Why?
|
Apolipoprotein C-III | 1 | 2019 | 211 | 0.150 |
Why?
|
Databases, Protein | 1 | 2020 | 387 | 0.150 |
Why?
|
North America | 1 | 2021 | 1276 | 0.150 |
Why?
|
Asthma | 1 | 2017 | 6234 | 0.150 |
Why?
|
Overweight | 3 | 2023 | 2417 | 0.150 |
Why?
|
Confidence Intervals | 2 | 2014 | 2927 | 0.150 |
Why?
|
Specimen Handling | 1 | 2022 | 702 | 0.140 |
Why?
|
Up-Regulation | 4 | 2019 | 4125 | 0.140 |
Why?
|
Plasma | 1 | 2020 | 586 | 0.140 |
Why?
|
Immunoassay | 2 | 2014 | 745 | 0.140 |
Why?
|
Heart Valves | 1 | 2019 | 284 | 0.140 |
Why?
|
Thyroid Hormones | 1 | 2020 | 404 | 0.140 |
Why?
|
Eicosanoids | 1 | 2019 | 282 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2010 | 4016 | 0.140 |
Why?
|
Age of Onset | 2 | 2021 | 3306 | 0.140 |
Why?
|
Respiratory Tract Infections | 1 | 2024 | 1010 | 0.130 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2017 | 186 | 0.130 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.130 |
Why?
|
Caloric Restriction | 1 | 2018 | 299 | 0.130 |
Why?
|
Severity of Illness Index | 5 | 2021 | 15843 | 0.130 |
Why?
|
Preventive Health Services | 1 | 2000 | 567 | 0.130 |
Why?
|
Prevalence | 6 | 2020 | 15733 | 0.120 |
Why?
|
Europe | 3 | 2016 | 3420 | 0.120 |
Why?
|
Lipid Metabolism | 2 | 2021 | 1902 | 0.120 |
Why?
|
Peptic Ulcer | 1 | 2016 | 217 | 0.120 |
Why?
|
Smoking | 4 | 2021 | 9053 | 0.120 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 973 | 0.120 |
Why?
|
Ion Transport | 1 | 2015 | 319 | 0.120 |
Why?
|
Algorithms | 4 | 2021 | 14033 | 0.120 |
Why?
|
Myocardial Revascularization | 2 | 2020 | 790 | 0.120 |
Why?
|
Chemoprevention | 1 | 2016 | 326 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 8 | 2021 | 17904 | 0.110 |
Why?
|
ROC Curve | 2 | 2015 | 3578 | 0.110 |
Why?
|
Blood Vessels | 1 | 2019 | 1113 | 0.110 |
Why?
|
Thyrotropin | 3 | 2024 | 834 | 0.110 |
Why?
|
Longitudinal Studies | 3 | 2020 | 14608 | 0.110 |
Why?
|
Physical Endurance | 2 | 2006 | 366 | 0.110 |
Why?
|
Homeostasis | 1 | 2024 | 3323 | 0.110 |
Why?
|
Cardiovascular System | 1 | 2021 | 834 | 0.110 |
Why?
|
Homocysteine | 2 | 2007 | 638 | 0.110 |
Why?
|
Ligands | 1 | 2020 | 3272 | 0.110 |
Why?
|
Health Status Indicators | 1 | 2018 | 970 | 0.110 |
Why?
|
Hematuria | 1 | 2014 | 233 | 0.110 |
Why?
|
Aged, 80 and over | 14 | 2021 | 58984 | 0.110 |
Why?
|
Fibroblast Growth Factors | 1 | 2018 | 867 | 0.100 |
Why?
|
Genotype | 7 | 2024 | 12990 | 0.100 |
Why?
|
Aorta, Thoracic | 1 | 2019 | 1096 | 0.100 |
Why?
|
Ultrasonography | 3 | 2012 | 5971 | 0.100 |
Why?
|
Calcium | 2 | 2023 | 5722 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1367 | 0.100 |
Why?
|
Body Composition | 1 | 2021 | 2426 | 0.100 |
Why?
|
Carotid Artery, Common | 1 | 2012 | 175 | 0.100 |
Why?
|
New England | 2 | 2024 | 1054 | 0.090 |
Why?
|
Reproducibility of Results | 6 | 2022 | 20100 | 0.090 |
Why?
|
Blood Proteins | 1 | 2016 | 1173 | 0.090 |
Why?
|
Endpoint Determination | 1 | 2013 | 590 | 0.090 |
Why?
|
Research | 1 | 2019 | 1982 | 0.090 |
Why?
|
Lipoproteins, IDL | 1 | 2010 | 18 | 0.090 |
Why?
|
Asymptomatic Diseases | 1 | 2013 | 588 | 0.090 |
Why?
|
Electronic Health Records | 2 | 2024 | 4811 | 0.090 |
Why?
|
Down-Regulation | 1 | 2017 | 2919 | 0.090 |
Why?
|
Early Termination of Clinical Trials | 1 | 2010 | 69 | 0.090 |
Why?
|
Triiodothyronine | 2 | 2024 | 493 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3597 | 0.080 |
Why?
|
Creatinine | 3 | 2020 | 1899 | 0.080 |
Why?
|
Single-Blind Method | 1 | 2013 | 1574 | 0.080 |
Why?
|
Carotid Artery, Internal | 1 | 2012 | 445 | 0.080 |
Why?
|
Odds Ratio | 3 | 2014 | 9647 | 0.080 |
Why?
|
Heart | 1 | 2022 | 4404 | 0.080 |
Why?
|
Middle East | 2 | 2020 | 231 | 0.080 |
Why?
|
Treatment Failure | 3 | 2021 | 2643 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2016 | 1116 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2020 | 2091 | 0.080 |
Why?
|
Migraine Disorders | 1 | 2021 | 1703 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2879 | 0.080 |
Why?
|
Thyroid Function Tests | 2 | 2020 | 288 | 0.080 |
Why?
|
Proteomics | 1 | 2022 | 3848 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 1248 | 0.080 |
Why?
|
Comorbidity | 4 | 2020 | 10508 | 0.080 |
Why?
|
Psoriasis | 1 | 2016 | 950 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2021 | 10766 | 0.070 |
Why?
|
Feeding Behavior | 1 | 2020 | 3188 | 0.070 |
Why?
|
Angioplasty | 1 | 2010 | 355 | 0.070 |
Why?
|
American Heart Association | 1 | 2012 | 1039 | 0.070 |
Why?
|
Arthritis, Rheumatoid | 1 | 2023 | 3763 | 0.070 |
Why?
|
Genome, Human | 2 | 2017 | 4425 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2000 | 3251 | 0.070 |
Why?
|
Hospitalization | 3 | 2022 | 10721 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 4853 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2020 | 5293 | 0.070 |
Why?
|
Health Behavior | 1 | 2018 | 2644 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2013 | 1530 | 0.070 |
Why?
|
Calibration | 1 | 2009 | 818 | 0.070 |
Why?
|
Communication | 1 | 2000 | 3875 | 0.070 |
Why?
|
Software | 1 | 2020 | 4434 | 0.070 |
Why?
|
Parathyroid Hormone | 2 | 2023 | 1803 | 0.060 |
Why?
|
Liver Diseases | 1 | 2014 | 1297 | 0.060 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 276 | 0.060 |
Why?
|
Muscular Diseases | 1 | 2010 | 553 | 0.060 |
Why?
|
Health Status | 1 | 2018 | 4077 | 0.060 |
Why?
|
Depressive Disorder, Major | 1 | 2023 | 4762 | 0.060 |
Why?
|
Waist Circumference | 2 | 2020 | 935 | 0.060 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1081 | 0.060 |
Why?
|
Vitamin B Complex | 1 | 2007 | 299 | 0.060 |
Why?
|
Massachusetts | 1 | 2017 | 8833 | 0.060 |
Why?
|
Kidney | 1 | 2020 | 7048 | 0.060 |
Why?
|
Primary Health Care | 1 | 2021 | 4687 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3688 | 0.060 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2012 | 993 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6815 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3429 | 0.060 |
Why?
|
Canada | 2 | 2022 | 2122 | 0.060 |
Why?
|
Death, Sudden, Cardiac | 1 | 2012 | 1555 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2850 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9319 | 0.050 |
Why?
|
Air Pollutants | 1 | 2017 | 2896 | 0.050 |
Why?
|
Inheritance Patterns | 1 | 2005 | 341 | 0.050 |
Why?
|
Child | 3 | 2021 | 80158 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5368 | 0.050 |
Why?
|
Data Collection | 1 | 2012 | 3322 | 0.050 |
Why?
|
Thrombosis | 2 | 2006 | 2942 | 0.050 |
Why?
|
Patient Selection | 1 | 2014 | 4244 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2006 | 376 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2008 | 14665 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2017 | 4485 | 0.050 |
Why?
|
Heart Arrest | 1 | 2012 | 1514 | 0.050 |
Why?
|
Diabetes Complications | 1 | 2008 | 1315 | 0.050 |
Why?
|
Isoleucine | 1 | 2021 | 110 | 0.050 |
Why?
|
Trace Elements | 1 | 2023 | 195 | 0.050 |
Why?
|
Adolescent | 4 | 2022 | 88326 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9327 | 0.050 |
Why?
|
Epidemiologic Methods | 2 | 2021 | 1336 | 0.050 |
Why?
|
Siblings | 1 | 2005 | 825 | 0.050 |
Why?
|
Intention to Treat Analysis | 1 | 2022 | 413 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2021 | 271 | 0.040 |
Why?
|
Prediabetic State | 1 | 2006 | 545 | 0.040 |
Why?
|
Genetic Loci | 1 | 2009 | 2632 | 0.040 |
Why?
|
Cation Transport Proteins | 1 | 2023 | 327 | 0.040 |
Why?
|
Family Health | 1 | 2005 | 1257 | 0.040 |
Why?
|
Fibrinolysis | 1 | 2021 | 332 | 0.040 |
Why?
|
Folic Acid | 1 | 2007 | 1323 | 0.040 |
Why?
|
Metabolic Networks and Pathways | 1 | 2024 | 789 | 0.040 |
Why?
|
Internet | 1 | 2012 | 3093 | 0.040 |
Why?
|
Africa, Northern | 1 | 2019 | 86 | 0.040 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2023 | 602 | 0.040 |
Why?
|
Nomograms | 1 | 2021 | 230 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 4431 | 0.040 |
Why?
|
Blood Coagulation Factors | 1 | 2021 | 365 | 0.040 |
Why?
|
Epidemiologic Studies | 1 | 2022 | 675 | 0.040 |
Why?
|
Plant Extracts | 1 | 2022 | 497 | 0.040 |
Why?
|
DNA | 2 | 2010 | 7213 | 0.040 |
Why?
|
Apolipoproteins E | 1 | 2024 | 1443 | 0.040 |
Why?
|
Femur Neck | 1 | 2020 | 314 | 0.040 |
Why?
|
Autocrine Communication | 1 | 1999 | 169 | 0.040 |
Why?
|
Myometrium | 1 | 1999 | 174 | 0.040 |
Why?
|
Muscles | 1 | 2023 | 1576 | 0.040 |
Why?
|
Linear Models | 2 | 2019 | 5872 | 0.040 |
Why?
|
Young Adult | 4 | 2022 | 59260 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2020 | 679 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 344 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2019 | 504 | 0.040 |
Why?
|
Phenotype | 3 | 2021 | 16592 | 0.040 |
Why?
|
Regression Analysis | 1 | 2007 | 6345 | 0.040 |
Why?
|
von Willebrand Factor | 1 | 2021 | 673 | 0.040 |
Why?
|
Bone Density | 2 | 2021 | 3551 | 0.040 |
Why?
|
Metabolome | 1 | 2024 | 989 | 0.040 |
Why?
|
Iodide Peroxidase | 1 | 2019 | 294 | 0.040 |
Why?
|
Paracrine Communication | 1 | 1999 | 277 | 0.040 |
Why?
|
Premenopause | 1 | 2021 | 1039 | 0.030 |
Why?
|
Attitude | 1 | 2022 | 775 | 0.030 |
Why?
|
Prolactin | 1 | 1999 | 625 | 0.030 |
Why?
|
Growth Substances | 1 | 1999 | 768 | 0.030 |
Why?
|
Animals | 4 | 2024 | 168475 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2021 | 1380 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7828 | 0.030 |
Why?
|
England | 1 | 2017 | 526 | 0.030 |
Why?
|
Glycomics | 1 | 2017 | 113 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2008 | 5493 | 0.030 |
Why?
|
Blood Coagulation | 1 | 2021 | 1154 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2019 | 1541 | 0.030 |
Why?
|
Netherlands | 1 | 2020 | 2221 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2019 | 803 | 0.030 |
Why?
|
Water | 1 | 2021 | 1411 | 0.030 |
Why?
|
Body Weight | 1 | 2005 | 4618 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2024 | 1998 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12973 | 0.030 |
Why?
|
Leiomyoma | 1 | 1999 | 636 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2020 | 1738 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1520 | 0.030 |
Why?
|
Minority Groups | 1 | 2020 | 1203 | 0.030 |
Why?
|
Pulse | 1 | 2013 | 217 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2000 | 2696 | 0.030 |
Why?
|
Survival Analysis | 1 | 2005 | 10090 | 0.030 |
Why?
|
Erythrocytes | 1 | 2022 | 2413 | 0.030 |
Why?
|
Autoantibodies | 1 | 2021 | 2118 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2019 | 1188 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 17354 | 0.030 |
Why?
|
Electrocardiography | 1 | 2005 | 6377 | 0.020 |
Why?
|
Nurses | 1 | 2021 | 2478 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2024 | 7054 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6312 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2018 | 1974 | 0.020 |
Why?
|
Quality of Life | 1 | 2012 | 13367 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2684 | 0.020 |
Why?
|
Uterine Neoplasms | 1 | 1999 | 1420 | 0.020 |
Why?
|
Viral Load | 1 | 2019 | 3332 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2019 | 3208 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2019 | 2095 | 0.020 |
Why?
|
Genetic Markers | 1 | 2015 | 2601 | 0.020 |
Why?
|
Biological Transport | 1 | 2013 | 2091 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3517 | 0.020 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2013 | 575 | 0.020 |
Why?
|
Plaque, Atherosclerotic | 1 | 2019 | 1532 | 0.020 |
Why?
|
Aging | 1 | 2006 | 8710 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2016 | 80647 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2015 | 2330 | 0.020 |
Why?
|
Smoking Cessation | 1 | 2018 | 2057 | 0.020 |
Why?
|
Cognition | 1 | 2024 | 6992 | 0.020 |
Why?
|
Models, Statistical | 1 | 2021 | 5079 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 4021 | 0.020 |
Why?
|
Logistic Models | 1 | 2000 | 13255 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3271 | 0.020 |
Why?
|
Patient Participation | 1 | 2014 | 1445 | 0.020 |
Why?
|
Quality of Health Care | 2 | 2009 | 4331 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6770 | 0.010 |
Why?
|
Gene Frequency | 1 | 2010 | 3606 | 0.010 |
Why?
|
Depression | 1 | 2023 | 8126 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6180 | 0.010 |
Why?
|
Hemodynamics | 1 | 2013 | 4160 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2011 | 3313 | 0.010 |
Why?
|
Models, Genetic | 1 | 2009 | 3442 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6864 | 0.010 |
Why?
|
Receptors, Prolactin | 1 | 1999 | 16 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1999 | 777 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 6075 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2691 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4243 | 0.010 |
Why?
|
Pregnancy | 1 | 2018 | 29890 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1999 | 1704 | 0.010 |
Why?
|
Cell Count | 1 | 1999 | 1835 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 13642 | 0.010 |
Why?
|
Mitosis | 1 | 1999 | 1188 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4576 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13381 | 0.010 |
Why?
|
Cell Division | 1 | 1999 | 4465 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 6131 | 0.010 |
Why?
|
Antibodies | 1 | 1999 | 2418 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1999 | 12794 | 0.000 |
Why?
|